Project Grant R00GM149928
- The National Institute of General Medical Sciences awarded the University of California Santa Cruz $425,033 on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to map variant histone protein interactions and elucidate the molecular mechanisms governing those interactions through advanced proteomics and structural biology. Over the five-year performance period (July 1, 2026 through April 30, 2031), the principal investigator will use nucleosome...
- The National Institute of General Medical Sciences awarded the University of Massachusetts Medical School $1.34 million on September 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the molecular mechanisms of histone octamer transfer activity in BAF chromatin remodeling complexes and their relationship to cancer formation and neurodevelopmental disorders. The research examines the ARID1A subunit of CBAF complexes, which is mutated in over 20...
- The National Institute of General Medical Sciences, a component of the Department of Health and Human Services, awarded $440,465 to the Massachusetts Institute of Technology on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop biophysical models of genome folding and function. Over the five-year performance period ending February 28, 2031, the award funds research into chromosome architecture and the mechanisms that shape it—motor-driven loop...
- The National Institute of General Medical Sciences awarded the University of Massachusetts Boston $425,333 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research on cellular and molecular mechanisms of stem and progenitor cell development during tissue homeostasis and after injury. The research uses the Drosophila melanogaster blood system as a model to examine how multiple cell types within stem and progenitor cell niches use inflammatory...
- The National Institute of General Medical Sciences awarded $463,375 to Harvard College on May 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research on evolution and population genetics in microbial populations. The research combines mathematical models and laboratory evolution experiments in budding yeast to characterize genotype-phenotype landscapes and analyze how microbial and viral populations evolve across those landscapes. The work examines...
- The National Science Foundation Division of Molecular and Cellular Biosciences awarded Brandeis University $370,052 on August 1, 2026, under the Biological Sciences program (CFDA 47.074) to investigate how intrinsically disordered regions in proteins regulate the search and binding of heterochromatin-associated proteins in living cells. The research aims to determine how dynamic recruitment and retention of histone H3 lysine 9 methylation-binding proteins establish stable and heritable gene...
- The National Science Foundation Division of Molecular and Cellular Biosciences awarded $1.5 million to Van Andel Research Institute on July 1, 2026, under the Biological Sciences program (CFDA 47.074) to investigate functional asymmetries of trans-histone and histone-DNA crosstalk in development. The research examines how asymmetric chemical modifications on histone proteins and DNA within individual nucleosomes work together to control gene expression during cell type specification. The project...
- The National Institute of General Medical Sciences awarded the Regents of the University of Minnesota $386,879 on May 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the mechanisms governing nucleosome dynamics and epigenetic inheritance during cell division. The research examines how parental histones transfer to newly replicated DNA strands during DNA replication and how this transfer regulates replication fork recovery under stress conditions....
- The National Institute of General Medical Sciences awarded the University of Wisconsin - Madison $152,600 on September 30, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate mechanisms of genomic organization by leveraging genetic divergence in Drosophila embryos. The research will determine how the nucleus partitions active and inactive chromatin compartments during early embryogenesis, focusing on the transcription factor GAGA factor (GAF). The...
- The National Institute of General Medical Sciences awarded The University of Chicago $480,083 on April 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate natural variation in embryo development across fly species, with performance through January 31, 2031, in Chicago, Illinois. The research compares developmental mechanisms across multiple Dipteran species to understand how embryonic gene networks evolve and acquire plasticity. The project...
The National Institute of General Medical Sciences awarded University of Massachusetts Boston $249,000 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the functional consequences of evolutionary innovation in histone H2A repertoires. The research uses evolutionary innovations in eukaryotic histone proteins to examine how histone repertoires have undergone lineage-specific changes and what selective advantages these changes confer. The project re-engineers ancestral eukaryotic H2A repertoires in yeast and Drosophila to identify functional consequences of evolved histone variants. Specific focus areas include expansion of prior findings that re-engineering an ancestral histone repertoire in S. cerevisiae resulted in impaired DNA damage response (DDR), elucidation of the mechanisms by which the evolved yeast repertoire increases DDR efficiency, and investigation of the Drosophila H2AV fusion histone variant, which the research demonstrates is essential for female fertility and transposon silencing in D. melanogaster. The work is performed in Seattle, Washington, with a period of performance running from September 1, 2026, through August 31, 2029. The award is structured as a Project Grant, the standard assistance type for investigator-initiated basic research awards under NIGMS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $249.0k | 7/23/26 |